Profound Medical Corp. PRN.TO

Company Overview

Profound Medical Corp. is a Canadian medical technology company focused on the development and commercialization of image-guided, minimally invasive therapeutic systems for the treatment of prostate disease, uterine fibroids, and other conditions. The company operates within the medical device and healthcare technology industries, with a primary emphasis on magnetic resonance imaging (MRI)-guided ultrasound therapies. Its core revenue drivers include sales and leasing of therapeutic systems, recurring consumables, service agreements, and procedure-related utilization associated with its proprietary platforms.

The company’s principal products are the TULSA-PRO system and the Sonalleve platform. TULSA-PRO is designed for MRI-guided transurethral ultrasound ablation of prostate tissue, including treatment for localized prostate cancer and benign prostatic hyperplasia. Sonalleve is an MRI-guided high-intensity focused ultrasound (HIFU) platform primarily used for uterine fibroids and palliative pain treatment for bone metastases in certain international markets. Profound Medical was founded in 2008 and evolved from an early-stage therapeutic ultrasound developer into a commercial-stage medical technology company with regulatory clearances in multiple jurisdictions, including the United States, Europe, and select Asian markets.

Business Operations

Profound Medical generates revenue through the commercialization of its TULSA-PRO and Sonalleve systems, including capital equipment sales, recurring consumable products, maintenance services, and treatment procedure utilization. The company’s operations are centered around MRI-guided therapeutic ultrasound technologies that combine real-time thermal imaging, software planning tools, and minimally invasive ablation techniques. The company maintains a strong focus on clinical validation and physician adoption, particularly in urology and interventional radiology settings.

The company operates primarily in North America and Europe, while also maintaining relationships with distributors and healthcare institutions in additional international markets. Profound Medical has collaborated with healthcare providers, imaging partners, and clinical research institutions to support adoption and clinical studies of its technologies. The company’s technologies rely on integration with MRI systems manufactured by major imaging providers, and commercial deployment often occurs through hospital-based cancer and specialty treatment centers.

Strategic Position & Investments

Profound Medical’s strategic direction is focused on expanding physician adoption of MRI-guided ultrasound therapies, increasing recurring procedural revenue, and broadening clinical indications for its platforms. A major component of its strategy has involved continued investment in clinical evidence generation, including studies evaluating prostate cancer treatment outcomes and quality-of-life measures associated with minimally invasive therapies. The company has also pursued reimbursement expansion initiatives in the United States to improve commercial accessibility for providers and patients.

The company continues to invest in software capabilities, treatment planning tools, and AI-assisted imaging workflows intended to improve procedural precision and efficiency. Profound Medical has emphasized growth in the prostate cancer treatment market, where TULSA-PRO competes as a minimally invasive alternative to surgery and radiation therapy. The company has also maintained development and commercialization efforts related to Sonalleve, particularly in international markets where MRI-guided focused ultrasound has broader clinical utilization. Public filings and investor disclosures indicate ongoing investments in commercialization infrastructure, physician training, and post-market clinical data collection.

Geographic Footprint

Profound Medical is headquartered in Mississauga, Ontario, Canada, and maintains operational activities across several international markets. The company’s largest commercial focus has been the United States, where TULSA-PRO received FDA clearance and where the company has concentrated physician training, reimbursement efforts, and hospital adoption initiatives. It also maintains a presence in Europe, where both TULSA-PRO and Sonalleve have been utilized in select healthcare systems and research institutions.

Beyond North America and Europe, the company has pursued opportunities in parts of Asia-Pacific and the Middle East through partnerships, distributors, and clinical collaborations. Its technologies are designed for integration into advanced hospital imaging environments, which has generally concentrated deployments in tertiary care centers and specialized oncology or urology facilities. International operations remain smaller in scale relative to the U.S. market based on available public disclosures.

Leadership & Governance

Profound Medical’s leadership team is composed of executives with backgrounds in medical devices, imaging technologies, oncology, and healthcare commercialization. The company’s governance structure includes a board of directors and executive leadership focused on clinical adoption, regulatory execution, and commercialization growth. Corporate strategy has consistently emphasized evidence-based expansion, regulatory compliance, and physician-centered adoption of minimally invasive therapies.

Key executives include:

• Arun Menawat – Chief Executive Officer and Chairman
• Mojgan Hodaie – Founder and Director
• Tim Dodd – Chief Financial Officer
• Adam Rankin – Chief Commercial Officer
• John McCutcheon – Chief Operating Officer
• Stephen Blazejewski – General Counsel and Corporate Secretary

The company’s leadership has publicly emphasized expanding the installed base of TULSA-PRO, increasing recurring treatment utilization, and strengthening long-term clinical evidence supporting MRI-guided therapeutic ultrasound technologies.